

# Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)

Technology appraisal guidance

Published: 25 April 2024

[www.nice.org.uk/guidance/ta968](https://www.nice.org.uk/guidance/ta968)

# Contents

|                  |   |
|------------------|---|
| Advice.....      | 3 |
| Information..... | 3 |

## Advice

NICE is unable to make a recommendation about the use in the NHS of melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides has confirmed that it does not intend to make an evidence submission for the appraisal. Oncopeptides considers that it has not yet been able to develop a cost-effectiveness model or complete the required literature reviews or indirect comparisons. So, it is uncertain whether it can make a high-quality submission at this time.

## Information

If NHS organisations wish to consider melphalan flufenamide with dexamethasone for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6048-4